Programme · 2016. 9. 3. · Programme European Forum Copenhagen 2016 Thursday 8th September 2016 The Marriott, Copenhagen, Denmark w ophthalmology-futures.com | e [email protected]

Programme

European Forum Copenhagen 2016

Thursday 8th September 2016The Marriott, Copenhagen, Denmark

w ophthalmology-futures.com | e [email protected] | t +44 (0) 207 099 6663 | m +44 (0) 7984 921 734

Alcon is the global leader in eye care, and our products touch the

lives of more than 260 million people each year living with

conditions like cataracts, glaucoma, retinal diseases

and refractive errors.

We are reimagining eye care through innovative products,

partnerships with eye care professionals and programs

that enhance access to quality eye care.

Learn more at www.alcon.com

© 2016 Novartis 7/16 1603N03G

Reimagining Eye Care.

1603N03G Corporate Ad_Opth Futures1603N03G Corporate Ad_Opth Futures.indd 1 8/3/16 11:17 AM

Ophthalmology Futures European Forum 2016 Copenhagen 2

Ophthalmology Futures European Forum 2016

Dear Colleagues,

Welcome to Ophthalmology Futures European Forum 2016. After successful meetings in Milan, Amsterdam, London and Barcelona, as well as our inaugural Asian Forum in Tokyo, we are delighted to be hosting our fifth European Forum in Copenhagen.

Each Forum aims to present new perspectives with regard to innovation in the ophthalmic sector. This meeting will focus on advances in cataract and refractive surgery, imaging, pharma, drug delivery, glaucoma and retinal disease. We hope that you will enjoy the meeting format and gain inspiration from the company presentations and timely panel discussions which highlight the breadth of innovation and investment in the field.

Ophthalmology Futures aims to provide a platform for communication for all professionals involved in ocular health. The panel sessions at this our sixth meeting will address the impact of recent technological advancements in eyecare, corporate strategies to promote innovation and growth, important regulatory issues and strategic partnerships within the ophthalmology sector throughout Europe and other regions of the world.

We should like to take this opportunity to thank our advisory board, programme committee, corporate presenters, sponsors and eminent faculty who take part in the panel discussions for their invaluable support and assistance.

The Ophthalmology Futures Team

Vision Futures Limited, London, UK registered in England No: 8125858

Alcon is the global leader in eye care, and our products touch the

lives of more than 260 million people each year living with

conditions like cataracts, glaucoma, retinal diseases

and refractive errors.

We are reimagining eye care through innovative products,

partnerships with eye care professionals and programs

that enhance access to quality eye care.

Learn more at www.alcon.com

© 2016 Novartis 7/16 1603N03G

Reimagining Eye Care.

1603N03G Corporate Ad_Opth Futures1603N03G Corporate Ad_Opth Futures.indd 1 8/3/16 11:17 AM

Ophthalmology Futures European Forum 2016 Copenhagen3

07:00 Registration

07:45-08:00 Introduction and WelcomeCo-Chairs: Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA

08:00-08:30 Panel 1: AMD – is the pipeline dry? Chair: Pravin Dugel Managing Partner, Retinal Consultants of Arizona, USA

Panellists: Eugene de Juan Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA

Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

José-Alain Sahel Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK

Andreas Wenzel Translational Medical Clinical Science Director, Novartis Institutes for BioMedical Research (NIBR), Switzerland

08:30-09:30 Company Presentations 1Co-Chairs: Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department

of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

08:30-08:37 Company: Apellis Cedric Francois Chief Executive Officer

08:37-08:44 Company: Second Sight Gregoire Cosendai Vice President, Europe

08:44-08:51 Company: Salutaris Medical DevicesTM Dr Laurence Marsteller Chief Executive Officer

08:51-08:58 Company: Cassini Jeroen Cameraat Chief Executive Officer i-Optics

08:58-09:05 Company: Kali Care Sina Fateh Founder and Chief Executive Officer

09:05-09:12 Company: Aerie Pharmaceuticals Inc. John Thygesen Associate Professor, Copenhagen University Hospital

09:12-09:19 Company: NightstaRx David Fellows Chief Executive Officer

09:19-09:30 Summary

Ophthalmology Futures European Forum 2016 Programme


09:30-10:00 Panel 2: Why is gene therapy not yet in the DNA of big pharma

Chair: José-Alain Sahel Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK

Panellists: Simon Chandler Senior Director, Clinical Research and Regulatory Operations, Ora Inc., UK

Vivian Choi Head of Gene Therapy Research, US Research and Non-clinical Development, Shire Pharmaceuticals, USA

Marc de Smet Chief Medical Officer, PRECEYES B.V, Switzerland

David Fellows Chief Executive Officer, NightstaRx, UK

Canwen Jiang Head of Global Clinical Development, Alcon, USA

Rogerio Vivaldi Chief Commercial Officer, Spark Therapeutics, USA

10:00-10:30 Panel 3: Imaging – OCT angiographyChair: Frank Holz Director and Chairman, Universitäts-Augenklinik Bonn, University of Bonn, Germany

Panellists: Eugene de Juan Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology,

University of California, San Francisco, USA

Pravin Dugel Managing Partner, Retinal Consultants of Arizona, USA

Ralf Kuschnereit Senior Vice President, Ophthalmic Systems Division, Carl Zeiss Meditec AG, Germany

Tien Yin Wong Senior Consultant, Retina Centre, Singapore National Eye Centre, Singapore

10:30-10:55 Coffee Break

10:55-12:10 Company Presentations 2Co-Chairs: Julian Stevens Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK

Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA

10:55-11:02 Company: Intelon Optics Inc. Dominik Beck President and Chief Executive Officer

11:02-11:09 Company: Avedro Rajesh Rajpal Chief Medical Officer

11:09-11:16 Company: Allotex Michael Mrochen Founder and Chief Executive Officer, IROC Science to Innovation

11:16-11:23 Company: EyeYon Medical Nahum Ferera Chief Operating Officer

11:23-11:30 Company: Altacor Ltd. Francesca E Crawford Chief Executive Officer

11:30-11:37 Company: Mynosys Inc. John N Hendrick President and Chief Executive Officer

11:37-11:44 Company: Z Lens LLC Paul M. Beer Founder and Chief Executive Officer

11:44-11:51 Company: LensGen Inc. Ramgopal Rao Chief Executive Officer

11:51-11:58 Company: AcuFocus Inc., USA Nicholas Tarantino Chief Clinical and Regulatory Officer, Head R&D

11:58-12:10 Summary


12:10-12:40 Panel 4: Trifocal and extended depth of focus Chair: Gerd Auffarth Chairman, Department of Ophthalmology, University of Heidelberg, Germany

Panellists: Alan Crandall John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA

Karlheinz Rein Vice President, Product Marketing Cataract and Retina Surgery, Carl Zeiss Meditec AG, Germany

MK Raheja Global Head, Corneal and Cataract Research and Development, Abbott, USA

Sunil Shah Consultant Ophthalmologist, Birmingham Children's Hospital and Honorary Consultant, Honorary Professor, The University of Ulster, UK

Nicholas Tarantino Chief Clinical and Regulatory Officer, Head R&D, AcuFocus Inc., USA

Ahmet Tezel Vice President, IOL R&D, Alcon, USA

12:40-13:40 Lunch

13:40-14:10 Panel 5: Tales around the campfire: Fireside chat with leading Venture Capitalists

Chair: Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners, UK

Panellists: Emmett Cunningham Partner, Clarus Ventures LLC, USA

Thomas Dyrberg Managing Partner, Novo Ventures, Denmark

Steven Fang Partner, CapBridge, Singapore

Johan Kördel Senior Partner, Lundbeckford Ventures, Denmark

Bobby Soni Director, Healthcare Ventures, Imperial Innovations, UK

14:10-14:40 Panel 6: Dry Eye: Will new science lubricate the markets? Co-Chairs: Leonard Borrmann Divisional Vice President, Research and Development, Abbott, USA

Alex Shortt Wellcome Trust Fellow, University College London, Honorary Consultant Ophthalmologist, Cornea and External Disease, Moorfields Eye Hospital, UK

Panellists: Eric Carlson Head of Strategic Operations and Planning, Alcon Research Labs Inc., USA

Seph Jensen Chief Executive Officer, TearLab Corporation, USA

George Ousler Vice President, Ora Inc., USA

Calvin Roberts Executive Vice President and Chief Medical Officer, Bausch+Lomb, USA

Baldo Scassellati Sforzolini Senior Vice President of Clinical Development, Allergan, USA

Amir Shojaei Vice President, Global Development lead, Ophthalmology and Transplant Medicine, Shire Pharmaceuticals Inc., USA

14:40-15:20 Company Presentations 3Chair: Donald Budenz, Professor and Chairman, Department of Ophthalmology, University of North Carolina

at Chapel Hill, USA

14:40-14:47 Company: InnFocus Inc. Russ Trenary President and Chief Executive Officer

14:47-14:54 Company: ALeyeGN Technologies LLC Michael Ballard President and Chief Executive Officer

14:54-15:03 Company: Ivantis Inc. Dave Van Meter President and Chief Executive Officer

15:03-15:10 Company: AQ BioMed Inc. Jim Kasic President and Chief Executive Officer

15:10-15:20 Summary

Ophthalmology Futures European Forum 2016 Programme continued


15:20-15:50 Coffee Break

15:50-16:20 Panel 7: MIGS - European Market Access Chair: Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

Panellists: Leon Au Consultant Ophthalmologist, Manchester Royal Eye Hospital, UK

Frank Ender Director Market Access Surgical, Europe, Middle East and Africa, Alcon Management SA, Switzerland

Tim Kelleher Director, Eye Innovation Consultants, Ireland

Greg Kunst Director, Global Market Access and New Business Planning, Glaukos Corporation, USA

Alexander Natz Director General Europe and Attorney at Law, Novacos Rechtsanwälte, Brussels

Rishi Rattan International Market Access Director, Eye Care, Allergan, UK

16:20-16:50 Panel 8: Capsule-centred IOLs Chair: Marie-José Tassignon Professor and Head of Department of Ophthalmology, Antwerp University Hospital,

Belgium

Panellists: Alan Crandall John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA

Boris Malyugin Chief of Department of Cataract and Implant Surgery and Deputy Director General, S.Fyodorov Eye Microsurgery Complex State Institution, Russia

Samuel Masket Clinical Professor of Ophthalmology, Geffen School of Medicine, UCLA, USA

Paul Rosen Consultant Ophthalmic Surgeon, Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK

Julian Stevens Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK

16:50-17:20 Panel 9: A View from the Top in 2016 - Corporate CEOsChair: James V. Mazzo Global President Ophthalmic Devices, Carl Zeiss Meditec, USA

Panellists: Mike Ball Chief Executive Officer, Alcon, USA

Ludwin Monz President and Chief Executive Officer, Carl Zeiss Meditec AG, Germany

Flemming Ørnskov Chief Executive Officer, Shire Plc, USA

Naveed Shams President and Chief Executive Officer, Santen Inc., USA

17:20-18:30 The Shark TankSee overleaf

18:30-18:40 Thank you and closing remarks from Keith Barton and Kuldev Singh

18:40-20:30 Cocktail Reception

Save the dateOphthalmology Futures Asian Forum will be held on the 28th of February 2017 at the Pan Pacific Hotel, Singapore.

Visit ophthalmology-futures.com for further information and updates.

Also, please visit our LinkedIn and Facebook groups for up to date discussions around Ophthalmology all year round.

Ophthalmology Futures European Forum 2017

Save the date 5th October 2017 Lisbon, Portugal

Keep up to date ophthalmology-futures.com

GLKOS-14346 ProTrade Ad-COS Final Program_92.5mm x 136.indd 8/31/16

4 0

136mm h x 92.5mm w 0"

COS FINAL PROGRAM AD

THIS IS YOUR OPENING.

800.GLAUKOS (452.8567) Glaukos.comINDICATION FOR USE. The iStent® Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication. CONTRAINDICATIONS. The iStent® is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS. Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent® is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details. PRECAUTIONS. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent® has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after “washout” of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract. ADVERSE EVENTS. The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information. CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

©2016 Glaukos Corporation. Glaukos and iStent are registered trademarks of Glaukos Corporation. 400-0285-2016-US Rev. 0

The complete procedure.

Make a once-in-a-lifetime difference with the safe MIGS procedure for cataract patients with glaucoma.

+

Agenda The Shark Tank

Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

Moderator

17:20-17:30 Introduction

17:30-17:45 Medicem – Eugen Chiceviç Chief Executive Officer

17:45-18:00 Implandata Ophthalmic Products GmbH – Max Ostermeier Managing Director

18:00-18:15 Elasmogen – Caroline Barelle, Elsamogen Ltd. Chief Executive Officer 1815-1830 The Vote

The Prey

The Sharks

Laurent Attias Senior Vice President, Head of Strategy, BD&L and Market Access, Alcon, USA

Thomas Dyrberg Managing Partner, Novo Ventures, Denmark

James V. Mazzo Global President Ophthalmic Devices, Carl Zeiss Meditec, USA

Jane Rady Divisional Vice President, Business Development, Abbott, USA

Calvin Roberts Executive Vice President and Chief Medical Officer, Bausch+Lomb, USA


www.alcon.com

www.santen.com

www.shire.com

Our Platinum Sponsors


Our Gold Sponsor

www.abbott.com

Apellis Pharmaceuticals:

Advancing the Treatment of

Geographic Atrophy through

Complement Immunotherapy

IN NOVATION

We cover all the daily

pharmaceutical needs of the ophthalmologist

AP CORPORATE 136.92.5 JUILLET 2015.indd 1 28/07/2015 10:18:16


Our Silver Sponsors

www.bausch.com

www.zeiss.com/med

www.acufocus.com

www.allergan.com


Our Bronze Sponsors

Our New Innovators

www.apellis.com www.oraclinical.com

www.medicem.comwww.lensgen.com

www.spectrum-thea.co.uk www.glaukos.com

“Pertinent topics to our industry and small companies showing what it takes to bring products to market and to treat patients.”

Leonard Borrmann Divisional Vice President, Research and Development, Abbott

Our Media Sponsors

“Your long-standing support for us via Ophthalmology Futures Forum was a tremendous podium for SalutarisMD getting our message out about episcleral brachytherapy.Our funding only came about because of, in part, Ophthalmology Futures Forum. Thank you!”

Laurence Marsteller Chief Executive Officer, Salutaris Medical Devices

“Many of the things that we see here are going to be making a difference in the lives of patients in five to seven years from now.”

Robert Warner Global Franchise Head, Vision Care, Alcon

MK-1276 Rev A

Improving Lifestyle Vision with Small Aperture Optics

Developing advanced, life-improving vision technologies for people of all ages.

www.abbottmedicaloptics.com

V I S I ON


Santen As a global ophthalmology company, Santen specializes in the research, development and commercialization of pharmaceutical, surgical, and OTC eye care products. With over 3,400 employees and its worldwide headquarters in Japan, Santen continues to grow its global presence across Asia, Europe, and North and South America. Santen is the market leader in Japan for prescription ophthalmic

pharmaceuticals and sells products in over 50 countries. Santen continues to provide innovative solutions in glaucoma, retina, uveitis, dry eye, ocular allergy and infection to patients around the world. For more information, please visit www.santen.com.

Alcon Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our products touch the lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is

reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Please visit www.alcon.com.

Abbott Medical Optics Inc. Abbott offers a comprehensive portfolio of cataract, refractive and eye care products. Cataract products include laser cataract technology, intraocular lenses, phacoemulsification systems and viscoelastics. Refractive products include wavefront diagnostic devices, femtosecond lasers and excimer laser vision correction systems. Eye care products include disinfecting solutions, lens rewetting drops and artificial tears.

Please visit www.abbott.com.

Our Platinum Sponsors

ShireShire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialised conditions.

Please visit www.shire.com.

Our Gold Sponsors


AcuFocus AcuFocus Inc. is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of near vision. The Company’s proven, proprietary technology platforms use a small aperture – or pinhole – effect to allow only focused light rays to reach the retina and bring objects

into focus. The result is unique, reliable and long-term. Using the small aperture concept, two products have been developed: the Company’s flagship product the KAMRA® corneal inlay and the innovative IC-8™ IOL. The KAMRA inlay helps presbyopic patients restore their near vision while maintaining their distance vision. It is commercially available in 50 countries, including the United States. The IC-8 IOL provides an uninterrupted range of vision from near to far and is specifically designed for patients with cataracts. The IOL is CE Marked and currently available in select markets. It is not approved by the FDA for use in the U.S. In addition to these products, AcuFocus also distributes the AcuTarget HD™ diagnostic and surgical planning instrument. This instrument is essential for optimal treatment and technology selection for a broad range of patients, including LASIK, cataract, dry eye and presbyopes. Founded in 2001, AcuFocus is based in Irvine, CA. For more information, visit www.AcuFocus.com.

Allergan Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals and biologic products for patients around the

world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Allergan is a leader in eye care, marketing a portfolio of products for the treatment of chronic dry eye disease and glaucoma, including RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15%, sterile, and COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, sterile. The Company also has nearly 20 eye care pipeline programs in mid-to-late stage development, including dry eye treatments OCU Tearbud and new delivery mechanisms and formulations of Restasis; potential new treatments for glaucoma including XEN 45 and Bimatoprost SR; and potential AMD and DME treatments within its DarPIN portfolio of programs.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. For more information, visit Allergan's website at www.Allergan.com.

Our Silver Sponsors

Bausch+Lomb Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely

focused on protecting, enhancing and restoring people’s eyesight. Our business offers the widest and finest range of eye health products including over-the-counter supplements, ophthalmic pharmaceuticals, contact lenses, lens care products and drops, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries. Please visit www.bausch.com.

BOLD FOR LIFE

We are a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Our world-class team develops, manufactures and commercializes innovative branded pharmaceuticals and biologic products for patients around the world.

We are one team of dedicated employees, carving new paths, taking bold, decisive actions to deliver results and better outcomes for patients and providers.

www.Allergan.com

Nothing is more important than the gift of sight.

© 2013 Bausch & Lomb Incorporated. Bausch + Lomb is a trademark of Bausch & Lomb Incorporated. PNS06827

There’s only one global company solely focused on protecting and enhancing that gift. We’re Bausch + Lomb, and we’ve been keeping the world’s eyes healthy for more than 160 years.

Visit Bausch.com/company


Our Bronze Sponsors

Apellis is a clinical stage biopharmaceutical company focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Apellis is currently evaluating its lead product candidates in Phase I and Phase

II clinical trials in paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy in age-related macular degeneration (AMD), and chronic obstructive pulmonary disease (COPD). For additional information about the company, please visit apellis.com.

Zeiss Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of ZEISS is rounded off by promising future technologies such as intraoperative radiation therapy. With approximately 2,900 employees worldwide, the Group generated revenue of €1,040 million in financial year 2014/2015 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries. Please visit www.zeiss.com/med.

Our Silver Sponsors

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of

blindness. We have pioneered Micro-Invasive Glaucoma Surgery (MIGS) in order to revolutionize the traditional glaucoma treatment and management paradigm.

We launched the iStent, our first MIGS device, in the United States in 2012. We are leveraging our platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. We believe the iStent is the smallest medical device ever approved by the Food and Drug Administration (FDA) measuring 1.0 mm long and 0.33 mm wide. Founded in 1989, Glaukos is a public company based in Laguna Hills, California. Glaukos generated net sales of approximately $72 million in 2015 and employs more than 150 people worldwide. Please visit glaukos.com.


MEDICEM is an integrated group of biomedical companies focusing on research, development and the commercialization of medical devices. One of the products represents the WIOL-CF - Bioanalogic intraocular lens: the new step in evolution of IOLs for the patients with cataract and presbyopia.

WIOL-CF has Supreme vision to far and intermediate, with restored reading capability, in all light conditions. Please visit www.medicem.com.

Our New InnovatorsLensGen® is a clinical stage ophthalmic device company focused on restoring youthful vision with a novel accommodating intraocular lens called Juvene™. The Juvene AIOL is designed to address all vision correction needs, including near vision (presbyopia) and emmetropia, representing the largest opportunity in ophthalmology.

The company, located in Irvine, California has a management team with over 100 years of combined ophthalmic industry experience and is guided by a world class team of scientific advisors and expert consultants.

Juvene is a modular Fixed and Fluid Lens system, with a Fixed Lens (similar to a standard IOL) and a Fluid Lens, that provides the accommodation, which is placed within the Fixed Lens. The fluid-based lens changes curvature, the most efficient way to achieve maximum accommodation.

Juvene fills the entire volume of the capsule, which stabilizes the lens position during the post-op healing process to achieve and maintain emmetropia. The modular design inherently facilitates a small incision procedure compatible with current cataract surgery. Juvene has gone through an extensive design optimization and testing process over the last four years and showing positive clinical data from pilot studies. Please visit www.lensgen.com.

Our Bronze Sponsors

Founded by Henri Chibret in 1994 from a R&D start-up company, Théa has played an important role in the latest pharmacological advances and in less than 10 years has risen to become the leading independent eye-care group in Europe. Now presided by Jean-Frédéric Chibret, the group is the leader in several therapeutic classes as well as in the field of preservative-free eye drops. Théa aims to

meet the full needs of all ophthalmologists, covering the main therapeutic classes. From well-known classics to innovative treatments, in the areas of diagnosis, surgery and therapeutics, Théa offers a complete range of modern products. Based in Clermont-Ferrand (France), the laboratory has continued to expand by opening nearly 25 subsidiaries in Europe, Russia, North Africa and South America. Currently, the Théa group constitutes a network uniting more than 900 collaborators worldwide, with its products available in more than 70 countries.Théa has always been committed to education and innovation, they will remain a constant priority. Please visit www.spectrum-thea.co.uk.

Ora, Inc. is the world's leading independent, full-service ophthalmic clinical research and product development firm. Over the past 35 years, it has helped clients earn 43 FDA approvals. Ora supports a wide array of organizations, from startups to global pharmaceutical and device companies, to efficiently and successfully bring their new products from concept to market. Ora’s pre-clinical and clinical

models, unique methodologies and regulatory strategies have been refined and proven across thousands of projects both in the US and internationally. Ora brings together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals in order to maximize the value of new product initiatives. For additional information, please visit oraclinical.com.


Co-chairs• Keith Barton Consultant Ophthalmologist,

Moorfields Eye Hospital, UK

• Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA

Organising Team• Melissa Murphy Operational Director, Vision

Futures Limited, London, UK

• Bhavika Tailor Programme Manager, Vision Futures Limited, London, UK

Advisors• Laurent Attias Senior Vice President, Head of

Strategy, BD&L and Market Access, Alcon, USA

• Leonard Borrmann Divisional Vice President Research and Development, Abbott, USA

• Emmett Cunningham Partner with Clarus Ventures LLC, USA

• Eugene de Juan Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA

• Tom Dunlap Supervisory Board Member, i-Optics BV. Executive Vice President, Sand Hill Consulting Associates, USA

• Malvina Eydelman Director, Division of Ophthalmic and Ear, Nose and Throat Devices ODE/CDRH/FDA, USA

• Akira Kurokawa Chief Executive Officer and President Santen Pharmaceutical Co.

• James V. Mazzo Global President Ophthalmic Devices, Carl Zeiss Meditec, USA

• Samir Patel Co-Founder and President of Ophthotech Corporation, USA

• Calvin Roberts Executive Vice President and Chief Medical Officer at Bausch+Lomb, USA

• Brent Saunders Chief Executive Officer and President, Allergan, USA

• Baldo Scasselati Sforzolini Senior Vice President of Clinical Development, Allergan, USA

• Naveed Shams President and Chief Executive Officer, Santen Inc., USA

• Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners, UK

• John Wilkinson Director of Devices, Medicines and Healthcare Products Regulatory Agency, UK

Programme Advisory Comittee

• Ike Ahmed Division Head, Ophthalmology, Trilium Health Partners, Assistant Professor, University of Toronto, Clinical Assistant Professor, University of Utah, USA

• Jorge Alio Professor and Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain

• Gerd Auffarth Chairman, Department of Ophthalmology, University of Heidelberg, Germany

• Francesco Bandello Full Professor and Chairman Department of Ophthalmology, Ospedale San Raffaele of Milan, Italy

• Beatrice Cochener Professor and Chairman, Ophthalmology Department, University Hospital Brest, France

• Paul Chew Professor of Ophthalmology, National University of Singapore, Singapore

• Burkhard Dick Professor of Ophthalmology, Chairman and Head of the University Eye Clinic Bochum, Germany

• Jack Holladay Clinical Professor of Ophthalmology at Baylor College of Medicine Houston, USA

• Frank Holz Director and Chairman Universitäts-Augenklinik Bonn, University of Bonn, Germany

• Jost Jonas Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany

• Sir Peng Khaw Professor of Glaucoma and Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, UK

• Richard Lindstrom Founder and Attending Surgeon, Minnesota Eye Consultants, Adjunct Professor Emeritus, University of Minnesota, Past President, ASCRS, ISRS\AAO; IIIC, IRSC, Chief Medical Editor, Ocular Surgery News, USA

• Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

• Boris Malyugin Chief of Department of Cataract and Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Russia

• Paul Rosen Consultant Ophthalmic Surgeon Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK

• Julian Stevens Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK

• Donald Tan Medical Director of the Singapore National Eye Centre (SNEC), Professor of Ophthalmology, National University of Singapore, Academic Chair, Ophthalmology Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore


• Laurent Attias Senior Vice President, Head of Strategy, BD&L and Market Access, Alcon, USA

• Leon Au Consultant Ophthalmologist, Manchester Royal Eye Hospital, UK

• Gerd Auffarth Chairman, Department of Ophthalmology, University of Heidelberg, Germany

• Mike Ball Chief Executive Officer, Alcon, USA

• Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

• Leonard Borrmann Divisional Vice President, Research and Development, Abbott, USA

• Donald Budenz Professor and Chairman, Department of Ophthalmology, University of North Carolina at Chapel Hill, USA

• Eric Carlson Head of Strategic Operations and Planning, Alcon Research Labs Inc., USA

• Simon Chandler Senior Director, Clinical Research and Regulatory Operations, Ora Inc., UK

• Vivian Choi Head of Gene Therapy Research, US Research and Non-clinical Development, Shire Pharmaceuticals, USA

• Alan Crandall John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA

• Emmett Cunningham Partner, Clarus Ventures LLC, USA

• Eugene de Juan Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA

• Marc de Smet Chief Medical Officer, PRECEYES B.V, Switzerland

• Pravin Dugel Managing Partner, Retinal Consultants of Arizona, USA

• Thomas Dyrberg Managing Partner, Novo Ventures, Denmark

• Frank Ender Director Market Access Surgical Europe, Middle East and Africa, Alcon Management SA, Switzerland

• Steven Fang Partner, CapBridge, Singapore

• Sina Fateh Founder and Chief Executive Officer, Kali Care, USA

• David Fellows Chief Executive Officer, NightstaRx, UK

• Frank Holz Director and Chairman, Universitäts-Augenklinik Bonn, University of Bonn, Germany

• Seph Jensen Chief Executive Officer, TearLab Corporation, USA

• Canwen Jiang Head of Global and Clinical Development, Alcon, USA

• Tim Kelleher Director, Eye Innovation Consultants, Ireland

• Johan Kördel Senior Partner, Lundbeckford Ventures, Denmark

• Greg Kunst Director, Global Market Access and New Business Planning, Glaukos Corporation, USA

• Ralf Kuschnereit Senior Vice President, Ophthalmic Systems Division, Carl Zeiss Meditec AG, Germany

• Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

• Boris Malyugin Chief of Department of Cataract and Implant Surgery and Deputy Director General, S.Fyodorov Eye Microsurgery Complex State Institution, Russia

List of Speakers and Affliations


• Samuel Masket Clinical Professor of Ophthalmology, Geffen School of Medicine, UCLA, USA

• James V. Mazzo Global President Ophthalmic Devices, Carl Zeiss Meditec, USA

• Ludwin Monz President and Chief Executive Officer, Carl Zeiss Meditec AG, Germany

• Alexander Natz Director General, Europe and Attorney at Law, Novacos Rechtsanwälte, Brussells

• Flemming Ørnskov Chief Executive Officer, Shire Plc, USA

• George Ousler Vice President, Ora Inc., USA

• Jane Rady Divisional Vice President, Business Development, Abbott, USA

• MK Raheja Global Head, Corneal and Cataract Research and Development, Abbott, USA

• Rishi Rattan International Market Access Director, Eye Care, Allergan, UK

• Karlheinz Rein Vice President, Product Marketing Cataract and Retina Surgery, Carl Zeiss Meditec AG, Germany

• Calvin Roberts Executive Vice President and Chief Medical Officer, Bausch+Lomb, USA

• Paul Rosen Consultant Ophthalmic Surgeon Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK

• José-Alain Sahel Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK

• Baldo Scassellati Sforzolini Senior Vice President of Clinical Development, Allergan, USA

• Sunil Shah Consultant Ophthalmologist, Birmingham Children's Hospital and Honorary Consultant, Honorary Professor, The University of Ulster, UK

• Naveed Shams President and Chief Executive Officer, Santen Inc., USA

• Amir Shojaei Vice President, Global Development lead, Ophthalmology and Transplant Medicine, Shire Pharmaceuticals Inc., USA

• Alex Shortt Wellcome Trust Fellow, University College London, and Honorary Consultant Ophthalmologist, Cornea and External Disease, Moorfields Eye Hospital, UK

• Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners, UK

• Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA

• Bobby Soni Director, Healthcare Ventures, Imperial Innovations, UK

• Julian Stevens Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK

• Nicholas Tarantino Chief Clinical and Regulatory Officer, Head R&D, AcuFocus Inc., USA

• Marie-José Tassignon Professor and Head of Department of Ophthalmology, Antwerp University Hospital, Belgium

• Ahmet Tezel Vice President, IOL R&D, Alcon, USA

• Rogerio Vivaldi Chief Commercial Officer, Spark Therapeutics, USA

• Andreas Wenzel Translational Medical Clinical Science Director, Novartis Institutes for BioMedical Research (NIBR), Switzerland

• Tien Yin Wong Senior Consultant, Retina Centre, Singapore National Eye Centre, Singapore


Notes

Carl Zeiss Meditec, Inc. 800 342 9821 www.zeiss.com/cirrusEN_31_025_0198I ©2016 Carl Zeiss Meditec, Inc. All copyrights reserved.

Making the revolutionary, routine. ZEISS AngioPlex OCT Angiography

A new era in retinal care—right now.

• New vascular information with ultra-clear 3D microvascular visualizations

• Enhanced workflow with non-invasive, dye-free, single-scan angiography

• Advancing OCT with ZEISS’ powerhouse CIRRUS™ OCT platform

www.zeiss.com/octangio


Mission Statement

An Ophthalmologist driven forum of corporate leaders, financiers, regulators, clinicians and scientists gathered to facilitate innovative

ophthalmic product development and improve eye care delivery.

Supporting improved ocular health.

“A meeting where we bring together innovators, ophthalmologists, venture capitalists, pharmaceutical and device manufacturers as well as regulators and market analysts.”

Kuldev Singh, Professor of Ophthalmology and Director of Glaucoma Service, Stanford

Supported Charities

Boston | London | Tokyo | Oraclinical.com | US: +1 (978) 332.9549 | UK: +44 (0) 1425.472291

Ora supports ophthalmology drug and device companies at all stages of product development with: CRO services, strategic consulting, preclinical research, regulatory strategy, clinical trial execution, data management, statistics, medical writing, manufacturing planning, life-cycle management, quality assurance, business development and financing.

APPROVAL

Nobody earns you more of these!

Nobody gets you there faster.

WE LOOK FORWARD TO HEARING FROM YOU

Hire the Ophthalmology R&D team that has delivered 43 product approvals.

Innovation is a messy business.

Uncertainty Clarity / Focus

Source: Adapted from Damien Newman, Central

Our motivation.Her eye disease.

To learn how Santen is advancing the ophthalmic field, visit www.santen.com.

Santen is proud to sponsor the 2016 Ophthalmology Futures Forum in Copenhagen

Image is designed to represent nondescript visual impairment and is not

intended to be medically accurate. For illustrative purposes only.

© 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 08/16

At Santen, our single focus in ophthalmology enables research of novel therapies in uveitis, glaucoma, and dry eye/corneal disorders—therapies determined to challenge eye disease, one patient at a time.

Documents

Programme · 2016. 9. 3. · Programme European Forum Copenhagen 2016 Thursday 8th September 2016 The Marriott, Copenhagen, Denmark w ophthalmology-futures.com | e [email protected]